System for interstitial photodynamic therapy with online dosimetry: First clinical experiences of prostate cancer

Journal of Biomedical Optics

Volumn 15, Issue 5, 2010, Pages

  Swartling, Johannes ^a   Axelsson, Johan ^b   Ahlgren, Göran ^c   Kälkner, Karl Mikael ^d   Nilsson, Sten ^d   Svanberg, Sune ^b   Svanberg, Katarina ^c   Andersson Engels, Stefan ^b  

^a SpectraCure AB   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biomedical optics; Laser applications; Photodynamic therapy; Spectrometry

Indexed keywords

BIOMEDICAL OPTICS; CANCER CELLS; CLINICAL EXPERIENCE; CLINICAL STUDY; FIBER POSITION; HISTOPATHOLOGICAL ANALYSIS; LIGHT DELIVERY; LOW LIGHT; ONLINE DOSIMETRY; PROSTATE CANCERS; PROSTATE TISSUE; REAL TIME; THRESHOLD DOSE; TISSUE BIOPSIES; TISSUE MODELS; TISSUE OPTICAL PROPERTIES; ULTRASOUND IMAGES;

DISEASES; DOSIMETRY; LASER APPLICATIONS; LIGHT; OPTICAL FIBERS; OPTICAL PROPERTIES; PLASMONS; THREE DIMENSIONAL; TISSUE;

PHOTODYNAMIC THERAPY;

MESOPORPHYRIN; PHOTOSENSITIZING AGENT; PROSTATE SPECIFIC ANTIGEN; TEMOPORFIN;

AGED; ARTICLE; BLOOD; COMPUTER ASSISTED RADIOTHERAPY; EVALUATION; HUMAN; IMAGE QUALITY; INSTRUMENTATION; LIGHT RELATED PHENOMENA; MALE; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ONLINE SYSTEM; PATHOLOGY; PHOTOCHEMOTHERAPY; PROSTATE TUMOR; THREE DIMENSIONAL IMAGING;

AGED; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MESOPORPHYRINS; MIDDLE AGED; ONLINE SYSTEMS; OPTICAL PHENOMENA; PHANTOMS, IMAGING; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 79952505158     PISSN: 10833668     EISSN: 15602281     Source Type: Journal    
DOI: 10.1117/1.3495720     Document Type: Article

References (28)

1. CM. Moore, D. Pendse, and M. Emberton, "Photodynamic therapy for prostate cancer - a review of current status and future promise," Nat. Clin. Pract. Urol. 6(1), 18-30 (January 2009).
2. J. Trachtenberg, A. Bogaards, R. A. Weersink, M. A. Haider, A. Evans, S. A. McCluskey, A. Scherz, M. R. Gertner, C. Yue, S. Appu, A. Aprikian, J. Savard, B. C. Wilson, and M. Elhilali, "Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response," J. Urol. 178(5), 1974-1979; discussion, 1979 (November 2007).
3. J. Trachtenberg, R. A. Weersink, S. R. H. Davidson, M. A. Haider, A. Bogaards, M. R. Gertner, A. Evans, A. Scherz, J. Savard, J. L. Chin, B. C. Wilson, and M. Elhilali, "Vascular-targeted photodynamic therapy (padoporfin, wst09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses," BJU Int. 102(5), 556-562 (August 2008).
4. K. L. Du, R. Mick, T. Busch, T. C. Zhu, J. C. Finlay, G. Yu, A. G Yodh, S. B. Malkowicz, D. Smith, R. Whittington, D. Stripp, and S. M. Hahn, "Preliminary results of interstitial motexafin lutetium-mediated pdt for prostate cancer," Lasers Surg. Med. 38(5), 427-434 (2006).
5. K. Verigos, D. C. H. Stripp, R. Mick, T. C. Zhu, R. Whittington, D. Smith, A. Dimofte, J. Finlay, T. M. Busch, Z. A. Tochner, S. B. Malkowicz, E. Glatstein, and S. M. Hahn, "Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer," J. Environ. Pathol. Toxicol. Oncol. 25(1-2), 373-387 (2006).
6. R. A. Weersink, A. Bogaards, M. Gertner, S. R. H. Davidson, K. Zhang, G. Netchev, J. Trachtenberg, and B. C. Wilson, "Techniques for delivery and monitoring of tookad (wst09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities," J. Photochem. Photobiol., B 79(3), 211-222 (2005).
7. B. C. Wilson and M. S. Patterson, "The physics, biophysics and technology of photodynamic therapy," Phys. Med. Biol. 53(9), R61-R109 (May 7, 2008).
8. X. D. Zhou, B. W Pogue, B. Chen, E. Demidenko, R. Joshi, J. Hoopes, and T. Hasan, "Pretreatment photosensitizer dosimetry reduces variation in tumor response," Int. J. Radiat. Oncol., Biol., Phys. 64(4), 1211-1220 (2006).
9. J. C. Finlay, T. C. Zhu, A. Dimofte, D. Stripp, S. B. Malkowcz, T. M. Busch, and S. M. Hahn, "Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy," Photochem. Photobiol. 82(5), 1270-1278 (2006).
10. A. Dimofte, T. C. Zhu, S. M. Hahn, and R. A. Lustig, "In vivo light dosimetry for motexafin lutetium-mediated pdt of breast cancer," Lasers Surg. Med. 31, 305-312 (2002).
11. J. Li and T. C. Zhu, "Determination of in vivo light fluence distribution in a heterogeneous prostate during photodynamic therapy," Phys. Med. Biol. 53(8), 2103-2114 (April 21, 2008).
12. T. M. Busch, E. P. Wileyto, M. J. Emanuele, F Del Piero, L. Marconato, E. Glatstein, and C. J. Koch, "Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen," Cancer Res. 62(24), 7273-7279 (2002).
13. T. M. Busch, "Local physiological changes during photodynamic therapy," Lasers Surg. Med. 38(5), 494-499 (June 2006).
14. H. W. Wang, T. C. Zhu, M. E. Putt, M. Solonenko, J. Metz, A. Dimofte, J. Miles, D. L. Fraker, E. Glatstein, S. M. Hahn, and A. G Yodh, "Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before and after photodynamic therapy," J. Biomed. Opt. 10, 014004 (2005).
15. S. R. Davidson, R. A. Weersink, M. A. Haider, M. R. Gertner, A. Bogaards, D. Giewercer, A. Scherz, M. D. Sherar, M. Elhilali, J. L. Chin, et al., "Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer," Phys. Med. Biol. 54(8), 2293-2313 (2009).
16. T. C. Zhu, A. Dimofte, J. C. Finlay, D. Stripp, T. Busch, J. Miles, R. Whittington, S. B. Malkowicz, Z. Tochner, E. Glatstein, and S. M. Hahn, "Optical properties of human prostate at 732 nm measured in vivo during motexafin lutetium-mediated photodynamic therapy," Photochem. Photobiol. 81(1), 96-105 (2005).
17. G. Q. Yu, T. Durduran, C. Zhou, T. C. Zhu, J. C. Finlay, T. M. Busch, S. B. Malkowicz, S. M. Hahn, and A. G. Yodh, "Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light," Photochem. Photobiol. 82(5), 1279-1284 (2006).
18. M. D. Altschuler, T. C. Zhu, J. Li, and S. M. Hahn, "Optimized interstitial pdt prostate treatment planning with the cimmino feasibility algorithm," Med. Phys. 32(12), 3524-3536 (2005).
19. J. Li, M. D. Altschuler, S. M. Hahn, and T. C. Zhu, "Optimization of light source parameters in the photodynamic therapy of heterogeneous prostate," Phys. Med. Biol. 53(15), 4107-4121 (2008).
20. T. Johansson, M. Soto Thompson, M. Stenberg, K. Claesaf, S. Andersson-Engels, S. Svanberg, and K. Svanberg, "Feasibility study of a system for combined light dosimetry and interstitial photodynamic treatment of massive tumors," Appl. Opt. 41(7), 1462-1468 (March 2002).
21. M. Soto-Thompson, A. Johansson, T. Johansson, S. Andersson-Engels, S. Svanberg, N. Bendsoe, and K. Svanberg, "Clinical system for interstitial photodynamic therapy with combined on-line dosimetry measurements," Appl. Opt. 44(19), 4023-4031 (July 2005).
22. A. Johansson, J. Axelsson, S. Andersson-Engels, and J. Swartling, "Realtime light dosimetry software tools for interstitial photodynamic therapy of the human prostate," Med. Phys. 34(11), 4309-4321 (November 2007).
23. A. Johansson, J. Axelsson, J. Swartling, T. Johansson, S. Palsson, J. Stensson, M. Einarsdottir, K. Svanberg, N. Bendsoe, K. M. Kalkner, S. Nilsson, S. Svanberg, and S. Andersson-Engels, "Interstitial photodynamic therapy for primary prostate cancer incorporating realtime treatment dosimetry," Proc. SPIE 6427, 64270O (2007).
24. C. M. Moore, T. R. Nathan, W. R. Lees, C. A. Mosse, A. Freeman, M. Emberton, and S. G. Bown, "Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mthpc) in early prostate cancer," Lasers Surg. Med. 38(5), 356-363 (2006).
25. C. M. Moore (personal communication).
26. T. Svensson, M. Einarsdottir, K. Svanberg, and S. Andersson-Engels, "In vivo optical characterization of human prostate tissue using near-infrared time-resolved spectroscopy," J. Biomed. Opt. 12(1), 014022 (2007).
27. T. Svensson, E. Alerstam, M. Einarsdottir, K. Svanberg, and S. Andersson-Engels, "Towards accurate in vivo spectroscopy of the human prostate," J. Biophoton. 1(3), 200-203 (2008).
28. E. Alerstam, S. Andersson-Engels, and T. Svensson, "Improved accuracy in time-resolved diffuse reflectance spectroscopy," Opt. Express 16(14), 10440-10454 (July 2008).